Is CV or NRXS more profitable?

CapsoVision has a net margin of -198.87% compared to NeurAxis' net margin of -492.76%. Company Net Margins Return on Equity Return on Assets CapsoVision -198.87% N/A -136.03% NeurAxis -492.76% N/A -641.25%

Which has higher valuation & earnings, NRXS or CNXU?

Conexeu Sciences has lower revenue, but higher earnings than NeurAxis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeurAxis $4.28M 19.67 -$14.63M -$0.81 N/A Conexeu Sciences N/A N/A N/A N/A N/A

Is NRXS or CNXU more profitable?

Conexeu Sciences has a net margin of 0.00% compared to NeurAxis' net margin of -492.76%. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% Conexeu Sciences N/A N/A N/A

Which has stronger valuation and earnings, ELMD or NRXS?

Electromed has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Electromed $71.75M 4.51 $5.15M $1.17 33.44 NeurAxis $4.28M 19.67 -$14.63M -$0.81 N/A

Is ELMD or NRXS more profitable?

Electromed has a net margin of 11.34% compared to NeurAxis' net margin of -492.76%. Electromed's return on equity of 15.71% beat NeurAxis' return on equity. Company Net Margins Return on Equity Return on Assets Electromed 11.34% 15.71% 13.37% NeurAxis -492.76% N/A -641.25%

Which has better valuation & earnings, CARL or NRXS?

NeurAxis has lower revenue, but higher earnings than Carlsmed. NeurAxis is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Carlsmed $50.51M 5.97 -$29.63M -$2.51 N/A NeurAxis $4.28M 19.67 -$14.63M -$0.81 N/A

Is CARL or NRXS more profitable?

Carlsmed has a net margin of -57.76% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Carlsmed's return on equity. Company Net Margins Return on Equity Return on Assets Carlsmed -57.76% -60.74% -29.84% NeurAxis -492.76% N/A -641.25%

Is SGHT or NRXS more profitable?

Sight Sciences has a net margin of -46.83% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Sight Sciences -46.83% -52.34% -28.49% NeurAxis -492.76% N/A -641.25%

NeurAxis (NRXS) Competitors

$6.80 -0.20 (-2.86%)

Closing price 04:00 PM Eastern

Extended Trading

$6.94 +0.14 (+1.99%)

As of 07:47 PM Eastern

Compare

NRXS vs. CV, CNXU, ELMD, CARL, and SGHT

Should you buy NeurAxis stock or one of its competitors? MarketBeat compares NeurAxis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeurAxis include CapsoVision (CV), Conexeu Sciences (CNXU), Electromed (ELMD), Carlsmed (CARL), and Sight Sciences (SGHT). These companies are all part of the "medical equipment" industry.

How does NeurAxis compare to CapsoVision?

CapsoVision (NASDAQ:CV) and NeurAxis (NASDAQ:NRXS) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

NeurAxis has lower revenue, but higher earnings than CapsoVision. NeurAxis is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	26.14	-$25.32M	-$2.34	N/A
NeurAxis	$4.28M	19.67	-$14.63M	-$0.81	N/A

11.8% of NeurAxis shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by company insiders. Comparatively, 21.1% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CapsoVision has a net margin of -198.87% compared to NeurAxis' net margin of -492.76%.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
NeurAxis	-492.76%	N/A	-641.25%

In the previous week, CapsoVision's average media sentiment score of 0.00 equaled NeurAxis'average media sentiment score.

Company	Overall Sentiment
CapsoVision	Neutral
NeurAxis	Neutral

CapsoVision presently has a consensus target price of $8.50, indicating a potential upside of 19.89%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 91.18%. Given NeurAxis' stronger consensus rating and higher probable upside, analysts plainly believe NeurAxis is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

CapsoVision and NeurAxis tied by winning 6 of the 12 factors compared between the two stocks.

How does NeurAxis compare to Conexeu Sciences?

NeurAxis (NASDAQ:NRXS) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Conexeu Sciences has lower revenue, but higher earnings than NeurAxis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$4.28M	19.67	-$14.63M	-$0.81	N/A
Conexeu Sciences	N/A	N/A	N/A	N/A	N/A

11.8% of NeurAxis shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NeurAxis currently has a consensus price target of $13.00, suggesting a potential upside of 91.18%. Conexeu Sciences has a consensus price target of $20.00, suggesting a potential upside of 87.09%. Given NeurAxis' higher probable upside, equities analysts plainly believe NeurAxis is more favorable than Conexeu Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Conexeu Sciences	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Conexeu Sciences has a net margin of 0.00% compared to NeurAxis' net margin of -492.76%.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Conexeu Sciences	N/A	N/A	N/A

In the previous week, Conexeu Sciences had 6 more articles in the media than NeurAxis. MarketBeat recorded 6 mentions for Conexeu Sciences and 0 mentions for NeurAxis. Conexeu Sciences' average media sentiment score of 1.08 beat NeurAxis' score of 0.00 indicating that Conexeu Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
NeurAxis	Neutral
Conexeu Sciences	Positive

Summary

NeurAxis and Conexeu Sciences tied by winning 4 of the 8 factors compared between the two stocks.

How does NeurAxis compare to Electromed?

Electromed (NYSE:ELMD) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

40.8% of Electromed shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 10.5% of Electromed shares are owned by company insiders. Comparatively, 21.1% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Electromed has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, NeurAxis has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

In the previous week, Electromed's average media sentiment score of 1.00 beat NeurAxis' score of 0.00 indicating that Electromed is being referred to more favorably in the media.

Company	Overall Sentiment
Electromed	Positive
NeurAxis	Neutral

Electromed has a net margin of 11.34% compared to NeurAxis' net margin of -492.76%. Electromed's return on equity of 15.71% beat NeurAxis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
NeurAxis	-492.76%	N/A	-641.25%

Electromed has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	4.51	$5.15M	$1.17	33.44
NeurAxis	$4.28M	19.67	-$14.63M	-$0.81	N/A

Electromed presently has a consensus target price of $37.50, suggesting a potential downside of 4.14%. NeurAxis has a consensus target price of $13.00, suggesting a potential upside of 91.18%. Given NeurAxis' higher possible upside, analysts plainly believe NeurAxis is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Electromed beats NeurAxis on 12 of the 16 factors compared between the two stocks.

How does NeurAxis compare to Carlsmed?

Carlsmed (NASDAQ:CARL) and NeurAxis (NASDAQ:NRXS) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

11.8% of NeurAxis shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NeurAxis has lower revenue, but higher earnings than Carlsmed. NeurAxis is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	5.97	-$29.63M	-$2.51	N/A
NeurAxis	$4.28M	19.67	-$14.63M	-$0.81	N/A

In the previous week, Carlsmed's average media sentiment score of 0.00 equaled NeurAxis'average media sentiment score.

Company	Overall Sentiment
Carlsmed	Neutral
NeurAxis	Neutral

Carlsmed presently has a consensus price target of $19.33, suggesting a potential upside of 74.33%. NeurAxis has a consensus price target of $13.00, suggesting a potential upside of 91.18%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts clearly believe NeurAxis is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Carlsmed has a net margin of -57.76% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
NeurAxis	-492.76%	N/A	-641.25%

Summary

NeurAxis beats Carlsmed on 9 of the 13 factors compared between the two stocks.

How does NeurAxis compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 30.9% of Sight Sciences shares are held by company insiders. Comparatively, 21.1% of NeurAxis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Sight Sciences presently has a consensus price target of $8.14, indicating a potential upside of 48.07%. NeurAxis has a consensus price target of $13.00, indicating a potential upside of 91.18%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts clearly believe NeurAxis is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

NeurAxis has lower revenue, but higher earnings than Sight Sciences. NeurAxis is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	3.87	-$38.43M	-$0.71	N/A
NeurAxis	$4.28M	19.67	-$14.63M	-$0.81	N/A

In the previous week, Sight Sciences had 1 more articles in the media than NeurAxis. MarketBeat recorded 1 mentions for Sight Sciences and 0 mentions for NeurAxis. Sight Sciences' average media sentiment score of 0.59 beat NeurAxis' score of 0.00 indicating that Sight Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Sight Sciences	Positive
NeurAxis	Neutral

Sight Sciences has a net margin of -46.83% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
NeurAxis	-492.76%	N/A	-641.25%

Sight Sciences has a beta of 2.41, indicating that its share price is 141% more volatile than the broader market. Comparatively, NeurAxis has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

Summary

Sight Sciences beats NeurAxis on 10 of the 16 factors compared between the two stocks.

Get NeurAxis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRXS vs. The Competition

Export

Metric	NeurAxis	Electromedical equipment Industry	Medical Sector	NASDAQ Exchange
Market Cap	$84.21M	$72.30M	$6.54B	$12.32B
Dividend Yield	N/A	N/A	2.68%	5.88%
P/E Ratio	-3.70	7.46	21.43	22.01
Price / Sales	19.67	191.35	530.17	107.90
Price / Cash	N/A	41.36	45.29	53.76
Price / Book	-25.19	5.00	10.76	6.41
Net Income	-$14.63M	-$5.50M	$3.56B	$337.14M
7 Day Performance	1.34%	2.48%	1.37%	-0.48%
1 Month Performance	-7.86%	-9.34%	0.81%	0.49%
1 Year Performance	178.69%	148.81%	30.53%	28.16%

NeurAxis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRXS NeurAxis	N/A	$6.80 -2.9%	$13.00 +91.2%	+195.4%	$84.21M	$4.28M	N/A	19
CV CapsoVision	1.1028 of 5 stars	$6.50 -2.0%	$8.50 +30.8%	N/A	$331.26M	$13.55M	N/A	90	High Trading Volume
CNXU Conexeu Sciences	4.7208 of 5 stars	$13.02 +4.0%	N/A	N/A	$329.02M	N/A	N/A	4	News Coverage Positive News Analyst Forecast Insider Trade Gap Up
ELMD Electromed	1.2446 of 5 stars	$37.14 -1.1%	$37.50 +1.0%	+81.3%	$307.52M	$71.75M	49.52	160	Positive News
CARL Carlsmed	N/A	$9.98 -5.6%	$19.33 +93.7%	N/A	$287.35M	$50.51M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRXS) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeurAxis (NRXS) Competitors

NRXS vs. CV, CNXU, ELMD, CARL, and SGHT

How does NeurAxis compare to CapsoVision?

Summary

How does NeurAxis compare to Conexeu Sciences?

Summary

How does NeurAxis compare to Electromed?

Summary

How does NeurAxis compare to Carlsmed?

Summary

How does NeurAxis compare to Sight Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeurAxis (NRXS) Competitors

NRXS vs. CV, CNXU, ELMD, CARL, and SGHT

How does NeurAxis compare to CapsoVision?

Which has higher valuation & earnings, CV or NRXS?

Do insiders and institutionals have more ownership in CV or NRXS?

Is CV or NRXS more profitable?

Does the media prefer CV or NRXS?

Do analysts recommend CV or NRXS?

Summary

How does NeurAxis compare to Conexeu Sciences?

Which has higher valuation & earnings, NRXS or CNXU?

Do insiders and institutionals have more ownership in NRXS or CNXU?

Do analysts recommend NRXS or CNXU?

Is NRXS or CNXU more profitable?

Does the media refer more to NRXS or CNXU?

Summary

How does NeurAxis compare to Electromed?

Do insiders & institutionals hold more shares of ELMD or NRXS?

Which has more volatility & risk, ELMD or NRXS?

Does the media prefer ELMD or NRXS?

Is ELMD or NRXS more profitable?

Which has stronger valuation and earnings, ELMD or NRXS?

Do analysts recommend ELMD or NRXS?

Summary

How does NeurAxis compare to Carlsmed?

Do institutionals and insiders hold more shares of CARL or NRXS?

Which has better valuation & earnings, CARL or NRXS?

Does the media refer more to CARL or NRXS?

Do analysts rate CARL or NRXS?

Is CARL or NRXS more profitable?

Summary

How does NeurAxis compare to Sight Sciences?

Do insiders and institutionals have more ownership in SGHT or NRXS?

Do analysts recommend SGHT or NRXS?

Which has higher earnings and valuation, SGHT or NRXS?

Does the media favor SGHT or NRXS?

Is SGHT or NRXS more profitable?

Which has more volatility and risk, SGHT or NRXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools